Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Coloplast A/S
  6. News
  7. Summary
    COLO B   DK0060448595

COLOPLAST A/S

(COLO B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Coloplast A/S : 9M 2020/21 roadshow presentation

08/18/2021 | 06:34am EST

Roadshow presentation

9M 2020/21

Making life easier

STRIVE25: SUSTAINABLE GROWTH

LEADERSHIP

'I love taking my boat out and I do so whenever I can.

Sometimes the weather stops me. But I won't let my

condition stop me.'

Flemming

Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology

Forward-looking statements

The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements are based on Coloplast's current expectations, estimates and assumptions and based on the information available to Coloplast at this time.

Heavy fluctuations in the exchange rates of important currencies, significant changes in the healthcare sector or major changes in the world economy may impact Coloplast's possibilities of achieving the long-term objectives set as well as for fulfilling expectations and may affect the company's financial outcomes.

Coloplast Group- Ostomy Care/ Continence Care / Wound & Skin Care /Interventional Urology

Page 2

Q3 organic growth of 11% and EBIT margin of 33% - financial guidance for FY 2020/21 narrowed

REVENUE GROWTH

Reported revenue (mDKK)

+3%

Organic growth

+6%

Reported growth

+9%

14,326

13,954

+11%

4,419

4,835

Q3 19/20 Q3 20/21 9M 19/20 9M 20/21

EBIT

EBIT (DKKm)

EBIT margin,

31

33

constant currencies (%)

33

4,382

4,705

Reported EBIT 31

margin (%)

1,368

1,592

Q3 19/20

Q3 20/21

9M 19/20

9M 20/21 1)

  1. Before special items of DKK 200m in Q2 20/21 related to the existing lawsuits in the US alleging injury resulting from the use of transvaginal surgical mesh products

Q3 Highlights

  • Organic growth of 11% and 9% reported growth in DKK
  • Organic growth rates by business area: Ostomy Care 4%, Continence Care 5%, Interventional Urology 82% and Wound & Skin Care 17%
  • Chronic Care was positively impacted by improving underlying growth in Europe as well as a lower baseline. Growth was partly offset by lower growth in new patients in the US due to COVID-19, in especially Continence Care, as well as distributor destocking
  • Ostomy Care delivered a softer quarter in Emerging markets due to tender phasing in the Middle East and Russia. The tenders are confirmed for delivery in Q4
  • Growth in new patients within Ostomy Care normalized towards pre-COVID levels during Q3. Continence Care is taking longer to normalize, but the trend during Q3 was positive
  • Interventional Urology growth was driven by broad-based recovery in elective procedures, led by the Men's Health portfolio in the US and a low baseline
  • Wound Care in isolation grew 20%, growth was driven by Europe and China, helped by a weaker comparison period
  • Reported EBIT margin of 33% against 31% in Q3 last year, positively impacted by efficiency gains and lower level of commercial activities, partly offset by continued investments
  • ROIC after tax was 42%
  • 2020/21 financial guidance narrowed
    • Organic revenue growth now expected in the lower end of the 7-8% range. Reported growth in DKK is still expected to be 4-5%
    • Reported EBIT margin before special items now expected in the upper end of the 32- 33% range. After special items, the reported EBIT margin is now expected to be in the upper end of the 31-32% range
    • Unchanged capex of around DKK 1.1bn and effective tax rate of around 23%

Page 3

We have made significant progress across the Clinical Performance

Program

Status October 2020

Status June 2021

Expected launch

Digital ostomy

Pilot studies conducted with

solution

successful results

Initial pilot studies indicated

New ostomy

positive outcomes

platform

Pivotal study showed non-

significant results

New catheter

Pilot studies conducted with

platform

successful results

  • CE mark has been granted
  • Payer pilot studies in Germany and the UK to be initiated in Q4 2021
  • Optimized product design
  • New pivotal study to be initiated towards the end of 2021
  • Solid progress on product design and performance
  • Pivotal study design ogress

Product launch expected in first half of strategy period

Product launch

expected in

second half of

strategy period

Product launch expected in first half of strategy period

Simultaneously, continue our launch cadence into existing categories within ostomy care and continence care

Page 4

Q3 growth was driven by a recovery in Interventional Urology led by

Men's Health and improving underlying growth in Europe

Q3 20/21 revenue by business area

Q3 20/21 revenue by geography

Business area

Ostomy Care

Continence Care

Interventional Urology

Wound & Skin Care

Coloplast

Group

Reported revenue Q3

Organic growth

Share of organic

DKKm

Q3

growth

4%

14%

1,915

1,744

5%

16%

542

82%

52%

634

17%

19%

4,835

11%

100%

Geographic area

European markets

Other developed markets

Emerging markets

Coloplast

Group

Reported revenue Q3

DKKm

2,844

1,183

808

4,835

Organic growth

Share of

Q3

organic growth

10%51%

17%36%

8%13%

11% 100%

Page 5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Coloplast A/S published this content on 18 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 August 2021 10:33:06 UTC.


ę Publicnow 2021
All news about COLOPLAST A/S
11/09Coloplast A/S - Announcement no. 10/2021 - Notice of Annual General Meeting
AQ
11/08GLOBAL MARKETS LIVE : Qiagen, Alcon, Boeing, Berkshire Hathaway...
11/08Coloplast to acquire Atos Medical in $2.5 billion deal, shares rise
RE
11/08Coloplast A/S - Announcement no. 09/2021 - Coloplast announces agreement to acquire Ato..
AQ
11/08COLOPLAST A/S (CPSE : COLO B) signed an agreement to acquire Atos Medical AB from PAI Euro..
CI
11/01Coloplast A/S Reports Earnings Results for the Full Year Ended September 30, 2021
CI
11/01Sustainability Report 2020/21
PU
11/01Remuneration Report 2020/21
PU
11/01Annual Report 2020/21
PU
11/01FY 2020/21 Interim Financial Report
PU
More news
Analyst Recommendations on COLOPLAST A/S
More recommendations
Financials
Sales 2022 21 186 M 3 238 M 3 238 M
Net income 2022 5 109 M 781 M 781 M
Net Debt 2022 2 125 M 325 M 325 M
P/E ratio 2022 44,7x
Yield 2022 1,82%
Capitalization 229 B 34 649 M 34 948 M
EV / Sales 2022 10,9x
EV / Sales 2023 10,0x
Nbr of Employees 12 728
Free-Float 57,4%
Chart COLOPLAST A/S
Duration : Period :
Coloplast A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COLOPLAST A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Last Close Price 1 074,50 DKK
Average target price 1 075,81 DKK
Spread / Average Target 0,12%
EPS Revisions
Managers and Directors
Kristian Villumsen President & Chief Executive Officer
Anders Lonning-Skovgaard Chief Financial Officer & Executive Vice President
Lars S°ren Rasmussen Chairman
Oliver Johansen Senior VP-Global Research & Development
Allan Rasmussen Executive Vice President-Global Operations